Department
Biomedical Sciences
Document Type
Article
Publication Title
PLoS ONE
ISSN
1932-6203
Volume
15
Issue
2
DOI
10.1371/journal.pone.0229311
First Page
e0229311
Publication Date
2-21-2020
Abstract
Glial cell-derived neurotrophic factor (GDNF) is reported to promote the survival of neurons and salivary gland regeneration after radiation damage. This study investigated the effect of GDNF on cell migration, growth, and response to radiation in preclinical models of head and neck squamous cell carcinoma (HNSCC) and correlated GDNF expression to treatment outcomes in HNSCC patients. Our ultimate goal is to determine whether systemic administration of GDNF at high dose is safe for the management of hyposalivation or xerostomia in HNSCC patients. Three HPV-positive and three HPV-negative cell lines were examined for cell migration, growth, and clonogenic survival in vitro and tumor growth assay in vivo. Immunohistochemical staining of GDNF, its receptors GFRα1 and its co-receptor RET was performed on two independent HNSCC tissue microarrays (TMA) and correlated to treatment outcomes. Results showed that GDNF only enhanced cell migration in two HPV-positive cells at supra-physiologic doses, but not in HPV-negative cells. GDNF did not increase cell survival in the tested cell lines post-irradiation. Likewise, GDNF treatment affected neither tumor growth in vitro nor response to radiation in xenografts in two HPV-positive and two HPV-negative HNSCC models. High stromal expression of GDNF protein was associated with worse overall survival in HPV-negative HNSCC on multivariate analysis in a combined cohort of patients from Stanford University (n = 82) and Washington University (n = 189); however, the association between GDNF gene expression and worse survival was not confirmed in a separate group of HPV-negative HNSCC patients identified from the Cancer Genome Atlas (TCGA) database. Based on these data, we do not believe that GNDF is a safe systemic treatment to prevent or treat xerostomia in HNSCC and a local delivery approach such as intraglandular injection needs to be explored.
Recommended Citation
Cao, H.,
He, Q.,
von Eyben, R.,
Bloomstein, J.,
Nambiar, D. K.,
Viswanathan, V.,
Aggarwal, S.,
Kwok, S.,
Liang, R.,
Koong, A. J.,
Lewis, J. S.,
Kong, C.,
Xiao, N.,
&
Le, Q.
(2020).
The role of Glial cell derived neurotrophic factor in head and neck cancer.
PLoS ONE, 15(2), e0229311.
DOI: 10.1371/journal.pone.0229311
https://scholarlycommons.pacific.edu/dugoni-facarticles/790
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
